Lemtrada Infusion Experience: Neurology Infusion Vs Nonneurology Infusion Centers

Thursday, June 2, 2016
Exhibit Hall
Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN , MS Center of Greater Orlando, Maitland, FL

Background: Alemtuzumab is a humanized monoclonal antibody for the treatment of relapsing multiple sclerosis (RMS). Alemtuzumab is an intravenous infusion given over at least four hours associated with Infusion Reactions (IRs). RMS causes many patients to have symptoms which are often worsened by stressors yielding a response similar to IRs, i.e. fever, fatigue, headache, and myalgia.

Objectives: The purpose of this assessment is to determine whether there is a difference in the patient’s satisfaction when they receive their Alemtuzumab in a Neurology based Infusion Center vs. a Hematology-Oncology based Infusion Center

Methods: All patients who were prescribed Alemtuzumab from a community based neurology practice will be given a satisfaction questionnaire to determine their satisfaction with the infusion experience. Some patients will be infused in the community neurology practice and others will be infused in a Hematology-Oncology practice. Results of the questionnaires will be compared between groups to asses for differences. Number of patients to be surveyed at least 35

Results: I have collected to date 12 surveys, I will have results prior to end of December but at this time not completed

Conclusions: Alemtuzumab is a highly effective disease modifying medication and has well described infusion associated reactions. These IRs can be managed and infusions can be given safely. Patient comfort is vital in ensuring all infusions are given.

            This assessment has limitations: one practice experience, infusion to survey time varied in this assessment but would be best to be done within 2-4 weeks after infusion, limited number of patients.